Correction to: Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: a cluster analysis with clinical and functional outcome prediction

Kate Haining¹ · Ruchika Gajwani² · Joachim Gross^{1,3} · Andrew I. Gumley² · Robin A. A. Ince¹ · Stephen M. Lawrie⁴ · Frauke Schultze-Lutter^{5,6,7} · Matthias Schwannauer⁸ · Peter J. Uhlhaas^{1,9}

Published online: 14 September 2021
© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to:
European Archives of Psychiatry and Clinical Neuroscience
<https://doi.org/10.1007/s00406-021-01315-2>

In the original article published, during typesetting, an erroneous correction in table 2 was performed. The word “Follow-up” has been changed to “Baseline”. Please see the correction of Table 2 below.”

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s00406-021-01315-2>.

✉ Peter J. Uhlhaas
peter.uhlhaas@charite.de

- ¹ Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK
- ² Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
- ³ Institute for Biomagnetism and Biosignalanalysis, University of Münster, Münster, Germany
- ⁴ Department of Psychiatry, University of Edinburgh, Edinburgh, UK
- ⁵ Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
- ⁶ Department of Psychology and Mental Health, Faculty of Psychology, Airlangga University, Surabaya, Indonesia
- ⁷ University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland
- ⁸ Department of Clinical Psychology, University of Edinburgh, Edinburgh, UK
- ⁹ Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

Table 2 Demographic, clinical and functional characteristics of the CHR-P group by cognitive cluster at baseline ($N=146$) and follow-up ($N=122$)

Baseline	Cluster 1 Impaired ($N=67$)	Cluster 2 Spared ($N=79$)	p	Effect size ^a
Age (years), mean (SD)	21.36 (4.63)	21.56 (3.86)	0.288	$r=0.088$
Sex, female n (%)	35 (52.2)	69 (87.3)	<0.001	$\phi=0.386$
Education (years), mean (SD)	14.96 (3.43)	15.25 (2.80)	0.421	$r=0.067$
CAARMS severity, median (range)	29 (0–74)	28 (0–72)	0.212	$r=0.103$
SPI-A severity, median (range)	6 (0–61)	7 (0–74)	0.883	$r=0.012$
GAF, median (range)	55 (21–87)	60 (21–95)	0.094	$r=0.139$
Social functioning (current), median (range)	7 (3–10)	8 (3–10)	<0.001	$r=0.296$
Role functioning (current), median (range)	7 (4–9)	8 (3–9)	0.002	$r=0.255$
PAS average, median (range)	1.36 (0–3.43)	0.86 (0–2.57)	<0.001	$r=0.405$
Comorbidity, n (%)				
Anxiety disorder	49 (73.1)	55 (69.6)	0.640	$\phi=0.039$
Mood disorder	50 (74.6)	47 (59.5)	0.054	$\phi=0.160$
Alcohol abuse/dependence	18 (26.9)	28 (35.4)	0.266	$\phi=0.092$
Substance abuse/dependence	11 (16.4)	13 (16.5)	0.995	$\phi=0.001$
Eating disorder	4 (6.0)	9 (11.4)	0.252	$\phi=0.095$
Psychological treatment, n (%)				
Current	15 (22.4)	10 (12.7)	0.120	$\phi=0.129$
Past	27 (40.3)	39 (49.4)	0.273	$\phi=0.091$
Medication, n (%)				
Antidepressants	25 (37.3)	28 (35.4)	0.815	$\phi=0.019$
Mood stabilisers	2 (3.0)	2 (2.5)	1.000	$\phi=0.014$
Antipsychotics	3 (4.5)	1 (1.3)	0.333	$\phi=0.098$
Anxiolytics	4 (6.0)	6 (7.6)	0.754	$\phi=0.032$
Follow-up	Cluster 1 Impaired ($N=57$)	Cluster 2 Spared ($N=65$)	p	Effect size ^a
GAF, median (range)	52 (21–88)	68 (33–88)	0.012	$r=0.227$
Poor functional outcome, n (%)	41 (71.9)	31 (47.7)	0.007	$\phi=0.246$
Social functioning (current), median (range)	8 (2–10)	8 (4–9)	0.021	$r=0.209$
Role functioning (current), median (range)	8 (4–9)	8 (5–9)	0.139	$r=0.134$
CAARMS severity, median (range)	15 (0–71)	12 (0–82)	0.886	$r=0.013$
CAARMS persistence, n (%)	17 (29.8)	21 (32.3)	0.768	$\phi=0.027$
Transitions ^b , n (%)	9 (15.8)	5 (7.7)	0.162	$\phi=0.127$

CHR-P clinical high-risk for psychosis; CAARMS Comprehensive Assessment of At-Risk Mental States; SPI-A Schizophrenia Proneness Instrument, Adult version; GAF Global Assessment of Functioning; PAS premorbid adjustment scale

^aEffect sizes were Rosenthal's r for Mann–Whitney U tests and Phi (ϕ) for Pearson's chi-square or Fisher's exact tests (small effect = 0.1, medium effect = 0.3, large effect = 0.5)

^b19 non-transitioned CHR-P individuals have yet to reach the 3-year follow-up